Skip to content
OpenCapital
Get started

Geron GERN Contract research organization and clinical trial costs

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's contract research organization and clinical trial costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's contract research organization and clinical trial costs?
Geron (GERN) reported contract research organization and clinical trial costs of $4.7M in Q1 2026.
How has Geron's contract research organization and clinical trial costs changed year-over-year?
Geron's contract research organization and clinical trial costs decreased by 55.3% year-over-year, from $10.5M to $4.7M.